News | March 01, 2023
NATCO launches generic Pomalidomide Capsules in Canada
Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules
Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic, and prostate cancer
At the end of the inspection, the facility received two observations, one on written production process control procedure and the other on investigation procedure
Both products are broad-spectrum, foliar insecticides used across wide range of crops
NATCO estimates the current market size of CTPR containing products in India to be over Rs. 2,000 crore.
NATCO is the first company in India to have received its registration approval given by Central Insecticide Board & Registration Committee (CIB&RC) for indigenous manufacture of Chlorantraniliprole
According to industry sales data, Yondelis generated annual sales of $49.7 million for the twelve months ending June 2022 in the US market.
The product will be launched by NATCO's commercial partner Viatris.
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
Subscribe To Our Newsletter & Stay Updated
